Biohaven Ltd.
HealthcareNYSE:BHVN · New York Stock Exchange
-$0.09 today
Vol 2.13M · Avg 2.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1418.8%
avg 442.2%
ROIC
-222.2%
avg -126.1%
ROA
-163.7%
avg -97.5%
Analysis
ROA is currently the strongest return metric at -163.7% versus its period average of -97.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vladimir Coric | Chairman & Chief Executive Officer | $1.40M | — | 55 | $550,000.00 | 0.52% |
Matthew Buten | Chief Financial Officer | $858,610.00 | — | 65 | $175,000.00 | 0.17% |
Bruce D. Car DACVP | Chief Scientific Officer | $801,361.00 | — | 64 | $175,000.00 | 0.17% |
Kimberly Gentile | Senior Vice President of Clinical Operations | $757,722.00 | — | 60 | $175,000.00 | 0.17% |
Warren Volles | General Counsel & Chief Legal Officer | — | — | — | — | — |
Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer | — | — | — | — | — |
George C. Clark | Vice President & Chief Accounting Officer | — | — | 41 | $50,000.00 | 0.05% |
John McGill | Chief Technology Officer | — | — | — | $68,693.00 | 0.06% |
Deb Young | Senior Director of Regulatory Affairs & Operations | — | — | — | — | — |
Jennifer Porcelli | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$33.14M
Sells
0
$0.00
Net Sentiment
+$33.14M
Net buying
Most Active
Coric Vlad
2 transactions
Analysis
Insiders reported 5 buys worth $33.14M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $33.14M. Coric Vlad was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
Who manages BHVN?
Biohaven Ltd. (BHVN) lists 10 active executives. The top listed executive is Warren Volles, General Counsel & Chief Legal Officer.
Are BHVN insiders buying or selling?
Recent insider activity shows net buying of $286.03M.
Explore More
Continue the stock analysis
Jump to another research area for this company.